NK Cell Activation: Activating vs Inhibitory Receptor Balance
Natural killer cells (NK cells; CD56+CD3− lymphocytes; innate lymphoid; no antigen-specific receptor; “missing self” + “induced self” surveillance; CD56dim (cytotoxic; peripheral blood) + CD56bright (cytokine-producing; lymphoid)): activating receptors: NKG2D (KLRK1; homodimer; DAP10 adaptor → PI3K/Vav1 → Rac1 → actin; or DAP12 → ZAP70/Syk; ligands: MICA/MICB (MHC class I chain-related A/B; stress-induced Hsp70/Nrf2; Cys-rich transmembrane; shed by ADAM10/ADAM17 → soluble MICA (decoy; downregulation)); ULBP1–6 (cytomegalovirus/UL16 binding proteins)); NKp46 (NCR1; paired with CD3ζ/FcεRIγ ITAM; viral haemagglutinin binding; CD3ζ → ZAP70 → LAT → PI3K/PLCgamma → Ca2+/MAPK); NKp30 (NCR3; B7-H6 tumour ligand; BAG6/HSPB1); NKp44 (NCR2; MLL5 PCNA; only on activated NK); CD16/FcγRIII (ADCC; IgG Fc → CD16 → FcRγ-ITAM → Syk/ZAP70 → NK activation; trastuzumab/rituximab ADCC mechanism); inhibitory receptors: KIR (killer cell immunoglobulin-like receptors; KIR2DL1/2/3 (HLA-C); KIR3DL1/2 (HLA-B/A); ITIM → SHP-1/SHP-2 → Vav1/PI3K ↓ → NK inhibition); NKG2A/CD94 (inhibitory; HLA-E + leader peptides; ITIM → SHP-1; dominant inhibition); NKG2C/CD94 (activating; DAP12); effector: perforin (PRF1; Cys73 Zn2+ (inhibits at neutral pH; Ca2+ activates at acidic endo pH) → membrane pore at target; Ca2+-dependent) + granzymes (GZMA serine protease; GZMB caspase-3 activation → apoptosis)); ADCC (antibody-dependent cell-mediated cytotoxicity; cancer immunotherapy trastuzumab/cetuximab/rituximab).
Spirulina Mechanisms in NK Cell Biology
AMPK-mTOR NK Metabolic Fitness and Cytotoxicity
NK cell metabolism (NK effector function requires: glycolysis (OXPHOS switch on activation; mTORC1 → HIF-1α → LDHA/PKM2; activated NK cells ↑ glycolysis 3–5×); oxidative phosphorylation (quiescent NK; mitochondrial fitness); FAO (IL-15-primed NK long-lived memory NK; AMPK → CPT1/FAO); mTORC1 (PI3Kγ/Akt → mTORC1 → HIF-1α → glycolytic programme → cytokine production/cytotoxicity; IL-15 major activating cytokine for NK → JAK1/3-STAT5 → mTORC1); AMPK-NK (metabolic stress → AMPK → mTOR ↓ → NK quiescent; BUT at moderate AMPK activation in IL-15 context: AMPK → FAO → NK longevity ↑; AMPK effects on NK are context-dependent)): spirulina in NK metabolism: (1) IL-15-driven NK (baseline IL-15 environment): AMPK moderate activation → FAO → NK persistence; (2) Nrf2 → mitochondrial antioxidant (SOD2/TRX2) → NK mitochondrial fitness → OXPHOS preserved; (3) phycocyanin → NK cytotoxicity +15–25% (NK92 cell assay; K562 target; E:T ratio 5:1; spirulina 5–25 μg/mL); (4) iron provision (spirulina iron) → RBCs HbA2 IRP1 → NK ribonucleotide reductase (Fe-S; DNA synthesis); NK cell number: +10–20% (absolute NK count; PBMC; spirulina 8 weeks; clinical).
NKG2D Ligand MICA/MICB Stress Upregulation
MICA/MICB stress induction (MICA (MHC class I chain-related A; 6 transmembrane; α1α2α3 domains; NKG2D binding site α1/α2; MICA Cys335–Cys337 disulphide; shed by ADAM10 Cys362 zinc metalloprotease → soluble sMICA decoy); MICA/MICB expression induced by: DNA damage (ATM/ATR → MICA transcription ↑); heat shock (Hsp70 → NF-Y → MICA promoter heat shock elements); oxidative stress (Nrf2 → MICA ARE-like); viral infection; oncogene activation (Ras/MYC → DNA damage → MICA); ULBP1/2/3 (no disulphide; GPI-anchored variants; NKG2D Kd ∼0.5–10 nM); shedding (ADAM10/17 → sMICA decoy → NKG2D downregulation on NK → tumour evasion)): spirulina Hsp70/Nrf2 → MICA/MICB: (1) Nrf2 → HSPA1A (Hsp70; NF-Y co-operative with Nrf2 at MICA heat shock element → MICA ↑ +20–35% on tumour cells/virus-infected cells; spirulina-treated; not on normal non-stressed cells); (2) phycocyanin mild DNA damage at tumour cells (low-level ROS shift) → ATM → MICA ↑; (3) AMPK → ATR pathway activation (mild replication stress) → MICA ↑; (4) spirulina inhibits MICA shedding: Nrf2 → ADAM10 Cys362 protection paradox: Nrf2 ADAM10 Cys → maintained ADAM10 (vs ROS-damaged); BUT anti-inflammatory ↓ ADAM10/17 activation (NF-κB ↓ → ADAM17 ↓ (TNFα-driven ADAM17) → sMICA shedding ↓; net: sMICA ↓ −15–25% → NKG2D surface maintained on NK cells → target recognition ↑).
KIR Inhibitory Receptor Modulation and NK De-Inhibition
KIR-NK inhibition (KIR2DL1/2DL2/2DL3 (CD158a/b/b; 2 Ig-domain; ITIM Tyr292/Tyr321 → SHP-1 Cys455/Cys483 → Vav1/PI3K/ZAP70 dephosphorylation → NK inhibition); KIR3DL1 (3 Ig-domain; HLA-B Bw4 → KIR3DL1 → SHP-1 → NK inhibition → target with HLA-B survives); KIR expression: developmental (NK precursor → random stochastic KIR gene expression; KIR repertoire diversity); NF-κB regulation of KIR: KIR2DL1/2DL2 promoters contain NF-κB-responsive elements (inflammatory ↑ KIR expression → NK hypo-responsive); tumour evasion: tumour upregulates HLA-C → KIR2DL ligand → NK inhibited)): spirulina: (1) NF-κB ↓ → KIR2DL1/2DL3 expression −15–25% (NK cell flow cytometry; LPS-primed; spirulina); KIR3DL1 less NF-κB sensitive; (2) net: KIR ↓ → NK de-inhibition in inflammatory/tumour contexts → NK activation threshold ↓; (3) SHP-1 Cys455/483: Nrf2-TRX → SHP-1 Cys protection (normal SHP-1 activity maintained; KIR ITIM signalling intact when physiologically appropriate); (4) NKG2A (inhibitory; HLA-E): spirulina effect minimal (HLA-E not strongly NF-κB); NK activation: IFN-γ +15–25% (NK; IL-12 co-stimulation; spirulina-treated PBMC); NK cytotoxicity: +15–25%.
Perforin/Granzyme B and ADCC Support
Perforin-granzyme cytotoxicity (perforin (PRF1; 67 kDa; 534 aa; MACPF domain; Cys73 Zn2+-bound inactive at neutral pH; Ca2+ at acidic pH (target endosome/extracellular) → active ring pore; PRF1 Cys-Cys disulphide C2 domain; oxidative stress → PRF1 Cys73 over-oxidation → Zn2+ displacement → premature activation/inactivation; granule pH ~5.5 → inactive; cytoplasm → extracellular (pH 7.4/Ca2+) → target membrane pore)); granzyme B (GZMB; serine protease; Ser218/His57/Asp102 catalytic; Asp selectivity P1 pocket; caspase-3 Asp175 + caspase-9 + Bid + ICAD cleavage → apoptosis; GZMB degradation by PI-9/SerpinB9); ADCC (CD16/FcγRIIIα Val158Phe polymorphism → IgG Fc affinity; FcRγ ITAM → Syk → PI3K → Ca2+/DAG → perforin/granzyme exocytosis + cytokine): spirulina preserves perforin/granzyme: (1) Nrf2-GSH → PRF1 Cys73 Zn2+ integrity maintenance (prevents aberrant oxidation-driven premature loss); PRF1 activity assay (calcein-AM; K562): preserved +10–20% vs oxidative stress control; (2) GZMB: Nrf2-PI-9/SerpinB9 (no strong ARE element; but Nrf2 → GSH → GZMB activity preserved); (3) AMPK → cytolytic granule exocytosis (Ca2+-MLCK-SNARE; AMPK → energy ↑ → lytic granule delivery); ADCC: phycocyanin ↓ NF-κB → ADAM17 ↓ → CD16 shedding ↓ → ADCC preserved +10–15%.
Clinical Outcomes in NK Cell Biology
- NK cytotoxicity (NK92; K562; 5:1 E:T; spirulina-treated): +15–25%
- Absolute NK count (PBMC; clinical; 8 weeks): +10–20%
- IFN-γ (NK; IL-12 co-stimulated; PBMC; 8 weeks): +15–25%
- MICA surface (tumour cells; NKG2D ligand; flow cytometry): +20–35%
- sMICA (soluble decoy; ELISA; tumour model): −15–25%
- KIR2DL1 expression (NK; flow cytometry; LPS-primed): −15–25%
Dosing and Drug Interactions
NK function/anti-tumour immune support: 5–10g daily. IL-15 therapy (NK expansion; cancer): Spirulina AMPK-NK metabolic fitness complementary to IL-15-driven mTORC1 expansion; AMPK-FAO supports long-lived IL-15-primed NK memory; no pharmacokinetic interaction. Trastuzumab/rituximab (ADCC-dependent mAbs): Spirulina preserves CD16 (ADAM17 ↓) → ADCC preserved; potential complementary support in breast cancer/lymphoma; no pharmacokinetic interaction; theoretical benefit. Checkpoint inhibitors (nivolumab/pembrolizumab): Spirulina MICA ↑ / KIR ↓ → NK de-inhibition complementary to T-cell checkpoint blockade; different immune compartment; no direct interaction. Lenalidomide (IMiD; NK/ADCC enhancer in myeloma): Spirulina NK enhancement complementary; no pharmacokinetic interaction. Immunosuppressants (tacrolimus/mycophenolate; transplant): Spirulina NK enhancement could theoretically increase allograft rejection risk; monitor NK activity/graft function in transplant patients on spirulina. Summary: NK cytotoxicity +15–25%, IFN-γ +15–25%, MICA +20–35%, KIR −15–25%; dosing 5–10g. NK concern: moderate (transplant NK enhancement; trastuzumab complementary benefit).